Stifel Maintains Buy on Insmed, Raises Price Target to $208

Benzinga Newsdesk www.benzinga.com Positive 79.3%

Neg 0% Neu 0% Pos 79.3%

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $205 to $208.

Comments

No comments yet. Be the first!